MODIFICATION
B -- Office of Clinical Pharmacology � Non-Clinical Studies and Laboratory Support
- Notice Date
- 7/20/2023 10:28:12 AM
- Notice Type
- Solicitation
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- FDA OFFICE OF ACQ GRANT SVCS Beltsville MD 20705 USA
- ZIP Code
- 20705
- Solicitation Number
- FDA-RFP-75F40123R00121
- Response Due
- 8/9/2023 11:30:00 AM
- Archive Date
- 08/24/2023
- Point of Contact
- Lillian Lamb, Phone: 301-796-1316
- E-Mail Address
-
lillian.lamb@fda.hhs.gov
(lillian.lamb@fda.hhs.gov)
- Description
- The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. The�services required under this effort may include target-based assays, safety pharmacology, ADME (absorption, distribution, metabolism, excretion), drug interaction assays/assessment, translational biology including biomarker evaluation, biotherapeutics characterization, or analyzing drug concentration in biological matrices on a task-by-task basis.� Note: This requirement was previously solicited under FDA-RFP-75F40122R00067.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/ecc3320b03c645d09068fc2ccae9a1e6/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN06756499-F 20230722/230720230046 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |